Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Other Liver Disease by Quarter
Other Liver Disease (Harvoni, Vosevi, Viread, Hepcludex, Sovaldi & Livdelzi prior to Q1 2026) — Europe sales ($M) ($M)
Gilead Sciences Other Liver Disease: $79M in Q2 2026, up 9.7% from a year earlier.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-06) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other Liver Disease (Harvoni, Vosevi, Viread, Hepcludex, Sovaldi & Livdelzi prior to Q1 2026) — Europe sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 79 | +9.7% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2026 | Mar 31, 2026 | 78 | +2.6% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2025 | Dec 31, 2025 | 97 | +79.6% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2025 | Sep 30, 2025 | 81 | +50.0% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 72 | +53.2% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 76 | +61.7% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 54 | +42.1% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 54 | +63.6% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2024 | Jun 30, 2024 | 47 | +27.0% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 47 | +14.6% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 38 | – | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2023 | Sep 30, 2023 | 33 | – | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 37 | – | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 41 | – | Form 10-Q (filed 2024-05-08) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Other Liver Disease ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-other-eu
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.